Market Overview

UPDATE: Barclays Raises PT to $57 on CVS Caremark Following Meeting with Management

Related CVS
Morgan Stanley Thinks CVS Surcharge May Replace Lost Tobacco Revenue
#PreMarket Primer: Tuesday, October 21: China's Third Quarter Growth Disappoints
Making Money With Charles Payne: 10/08/14 (Fox Business)

Barclays reiterated its Overweight rating on CVS Caremark (NYSE: CVS) and raised its price target from $54 to $57.

Barclays noted, "At CVS Caremark's 2012 analyst meeting, management showed investors how the company's business model gives it meaningful competitive advantages as the US healthcare industry is transformed. [P]erhaps most significant, is the change in rationale for payments to healthcare providers, especially doctors and hospitals, as the nation moves from fee-for-service to outcomes-based payment. We see many approaches to pay-for-performance, but encouraging patients to remain adherent to their medications is crucial to all of them."

CVS Caremark closed at $49.24 on Friday.

Latest Ratings for CVS

DateFirmActionFromTo
Sep 2014Cowen & CompanyUpgradesMarket PerformOutperform
Aug 2014BarclaysMaintainsOverweight
Aug 2014JP MorganMaintainsOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: BarclaysAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters